Charles Schwab
PRLD icon

Charles Schwab’s Prelude Therapeutics PRLD Stock Holding History

Charles Schwab’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$360K Buy
+67,622
New +$294K ﹤0.01% 3299
2025
Q3 		– Sell
-80,845
Closed -$65.4K – 3521
2025
Q2 		$65.4K Sell
80,845
-33,205
-29% -$28.8K ﹤0.01% 3437
2025
Q1 		$87.6K Sell
114,050
-3,150
-3% -$2.94K ﹤0.01% 3362
2024
Q4 		$149K Sell
117,200
-16,049
-12% -$21.3K ﹤0.01% 3359
2024
Q3 		$276K Buy
133,249
+5,216
+4% +$24.2K ﹤0.01% 3301
2024
Q2 		$488K Buy
128,033
+663
+0.5% +$2.7K ﹤0.01% 3205
2024
Q1 		$604K Buy
127,370
+2,670
+2% +$10.4K ﹤0.01% 2956
2023
Q4 		$532K Buy
124,700
+1,669
+1% +$5.08K ﹤0.01% 3059
2023
Q3 		$380K Buy
123,031
+37,238
+43% +$140K ﹤0.01% 3148
2023
Q2 		$386K Buy
85,793
+22,942
+37% +$137K ﹤0.01% 3165
2023
Q1 		$358K Sell
62,851
-870
-1% -$5.31K ﹤0.01% 3049
2022
Q4 		$385K Buy
63,721
+9,669
+18% +$62K ﹤0.01% 3062
2022
Q3 		$358K Sell
54,052
-9,148
-14% -$61.7K ﹤0.01% 3087
2022
Q2 		$330K Sell
63,200
-12,730
-17% -$64.8K ﹤0.01% 3178
2022
Q1 		$524K Sell
75,930
-9,207
-11% -$84.2K ﹤0.01% 3089
2021
Q4 		$1.06M Buy
85,137
+1,152
+1% +$18.7K ﹤0.01% 2888
2021
Q3 		$2.63M Buy
83,985
+11,362
+16% +$368K ﹤0.01% 2636
2021
Q2 		$2.08M Sell
72,623
-2,045
-3% -$72.8K ﹤0.01% 2706
2021
Q1 		$3.24M Buy
74,668
+6,100
+9% +$405K ﹤0.01% 2502
2020
Q4 		$4.91M Buy
+68,568
New +$3.41M ﹤0.01% 2230

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Charles Schwab's PRLD Position: Q2 2026 in Review

Charles Schwab opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 67,622 shares worth $360K. The stake represents ﹤0.01% of the portfolio and ranks #3299 among its holdings. This is a return to the name: Charles Schwab previously reported a position in PRLD as recently as Q2 2025.

Charles Schwab first reported a position in PRLD in Q4 2020 and has held it in 20 quarters since. The position peaked at $4.91M in Q4 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Charles Schwab held 67,622 shares of Prelude Therapeutics worth $360K as of Q2 2026.
  • Prelude Therapeutics was a new Charles Schwab position in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3299 holding.
  • Charles Schwab first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Charles Schwab's Prelude Therapeutics position peaked at $4.91M in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.